GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (NAS:ONC) » Definitions » Total Assets

ONC (BeiGene) Total Assets : $5,921 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BeiGene Total Assets?

BeiGene's Total Assets for the quarter that ended in Dec. 2024 was $5,921 Mil.

During the past 12 months, BeiGene's average Total Assets Growth Rate was 25.10% per year. During the past 3 years, the average Total Assets Growth Rate was 19.80% per year. During the past 5 years, the average Total Assets Growth Rate was 38.10% per year. During the past 10 years, the average Total Assets Growth Rate was 83.10% per year.

During the past 12 years, BeiGene's highest 3-Year average Total Assets Growth Rate was 206.40%. The lowest was 19.80%. And the median was 65.70%.

Total Assets is connected with ROA %. BeiGene's annualized ROA % for the quarter that ended in Dec. 2024 was -10.34%. Total Assets is also linked to Revenue through Asset Turnover. BeiGene's Asset Turnover for the quarter that ended in Dec. 2024 was 0.19.


BeiGene Total Assets Historical Data

The historical data trend for BeiGene's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Total Assets Chart

BeiGene Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,600.76 8,535.53 6,379.29 5,805.28 5,920.91

BeiGene Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,805.28 5,667.68 5,712.18 5,830.86 5,920.91

BeiGene Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BeiGene's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=3332.222+2588.688
=5,921

BeiGene's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=3332.222+2588.688
=5,921

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BeiGene  (NAS:ONC) Total Assets Explanation

Total Assets is connected with ROA %.

BeiGene's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-607.524/( (5830.86+5920.91)/ 2 )
=-607.524/5875.885
=-10.34 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BeiGene's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=1127.824/( (5830.86+5920.91)/ 2 )
=1127.824/5875.885
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BeiGene Total Assets Related Terms

Thank you for viewing the detailed overview of BeiGene's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


BeiGene Business Description

Address
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
Executives
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Xiaodong Wang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Hillhouse Capital Advisors, Ltd. 10 percent owner OFFICE #122, WINDWARD 3 BUILDING, REGATTA OFFICE PARK, WEST BAY ROAD, GRAND CAYMAN E9 KY1-9006
John Oyler director, 10 percent owner, officer: Chief Executive Office C/O GENTA INC, 3550 GENERAL ATOMICS CT BLDG 9, SAN DIEGO CA 92121
Chan Henry Lee officer: SVP, General Counsel 55 CAMBRIDGE PARKWAY, SUITE 700W, CAMBRIDGE MA 02142
Lai Wang officer: Global Head of R&D C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Xiaobin Wu officer: President and GM China C/O MOURANT OZANNES CRP SVCS CAYMAN LTD, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Julia Aijun Wang officer: Chief Financial Officer C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Alessandro Riva director C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Margaret Dugan director C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVE, CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Jane Huang officer: CMO, Hematology C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Amgen Inc 10 percent owner ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320
Howard Liang officer: CFO & CSO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Timothy Yung-cheng Chen director LSI LOGIC CORP, 1621 BARBER LANE, MILPITAS CA 95035